Join the Santagata Lab at Brigham and Women’s Hospital (BWH) to support a multidisciplinary research program developing targeted therapies for rare pediatric and adult brain tumors. The work focuses on identifying and validating therapeutically actionable cell-surface proteins, particularly targets for antibody-drug conjugates (ADCs) and other emerging targeted therapies. The program addresses challenges including limited tissue availability, biological heterogeneity, and a lack of effective targeted treatments for rare brain tumors. The role uses advanced tissue-imaging and spatial molecular technologies to quantitatively characterize therapeutic targets in patient tumor specimens and patient-derived models. Methods include cyclic immunofluorescence (CyCIF), ORION whole-slide multiplexed imaging, conventional immunohistochemistry and immunofluorescence, and integration with spatial transcriptomic data. Tumor types include ependymoma, craniopharyngioma, atypical teratoid/rhabdoid tumor, pediatric high-grade glioma, rare meningiomas, embryonal tumors, and other molecularly defined tumors. A central goal is to assess whether drugs developed for more common cancers may be repurposed for rare brain tumors based on quantitative measurements of therapeutic-target expression. The successful candidate will be based in Dr. Sandro Santagata’s laboratory at BWH and collaborate with investigators at Harvard Medical School’s Laboratory of Systems Pharmacology, Dana-Farber Cancer Institute, Boston Children’s Hospital, and other laboratories. The position offers hands-on experience in high-dimensional tissue imaging, antibody qualification, assay development, image analysis, and integration of molecular and morphologic data from human tumors.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level